AU2021307245B2 - Crystal of pyrimidine compound - Google Patents

Crystal of pyrimidine compound Download PDF

Info

Publication number
AU2021307245B2
AU2021307245B2 AU2021307245A AU2021307245A AU2021307245B2 AU 2021307245 B2 AU2021307245 B2 AU 2021307245B2 AU 2021307245 A AU2021307245 A AU 2021307245A AU 2021307245 A AU2021307245 A AU 2021307245A AU 2021307245 B2 AU2021307245 B2 AU 2021307245B2
Authority
AU
Australia
Prior art keywords
crystal
leu
compound
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021307245A
Other languages
English (en)
Other versions
AU2021307245A1 (en
Inventor
Takahiro Asai
Hiroyuki Nakamura
Hiroyoshi Yamanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of AU2021307245A1 publication Critical patent/AU2021307245A1/en
Application granted granted Critical
Publication of AU2021307245B2 publication Critical patent/AU2021307245B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Liquid Crystal Substances (AREA)
AU2021307245A 2020-07-15 2021-07-14 Crystal of pyrimidine compound Active AU2021307245B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-121520 2020-07-15
JP2020121520 2020-07-15
PCT/JP2021/026460 WO2022014638A1 (ja) 2020-07-15 2021-07-14 ピリミジン化合物の結晶

Publications (2)

Publication Number Publication Date
AU2021307245A1 AU2021307245A1 (en) 2023-03-02
AU2021307245B2 true AU2021307245B2 (en) 2024-02-29

Family

ID=79554693

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021307245A Active AU2021307245B2 (en) 2020-07-15 2021-07-14 Crystal of pyrimidine compound

Country Status (12)

Country Link
US (1) US12492208B2 (https=)
EP (1) EP4183788A4 (https=)
JP (1) JP7391226B2 (https=)
KR (1) KR102914926B1 (https=)
CN (1) CN116249534B (https=)
AU (1) AU2021307245B2 (https=)
BR (1) BR112023000765A2 (https=)
MX (1) MX2023000692A (https=)
MY (1) MY207540A (https=)
PH (1) PH12023550116A1 (https=)
TW (1) TWI905228B (https=)
WO (1) WO2022014638A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351737A4 (en) * 2021-05-24 2025-05-14 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065898A2 (en) * 2008-12-05 2010-06-10 Principia Biopharma Inc. Egfr kinase knockdown via electrophilically enhanced inhibitors
WO2013118817A1 (ja) * 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) * 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101852738B1 (ko) * 2015-01-30 2018-04-27 다이호야쿠힌고교 가부시키가이샤 축합 피리미딘 화합물의 신규한 염 및 그 결정
JP6537601B2 (ja) * 2015-05-12 2019-07-03 大鵬薬品工業株式会社 アザ二環式化合物の結晶
KR102674711B1 (ko) * 2017-02-28 2024-06-12 다이호야쿠힌고교 가부시키가이샤 피라졸로[3,4-d]피리미딘 화합물을 사용한 항종양 효과 증강제
WO2020004546A1 (ja) 2018-06-28 2020-01-02 日本電気株式会社 遠隔制御装置、遠隔制御方法及びプログラム
MA53509A (fr) 2018-08-29 2021-07-07 Taiho Pharmaceutical Co Ltd Agent thérapeutique contenant un composé pyrazolo[3,4-d]pyrimidine comme ingrédient actif
PL3909584T3 (pl) * 2019-01-11 2024-03-25 Taiho Pharmaceutical Co., Ltd. Związek pirymidynowy lub jego sól
JP7164455B2 (ja) 2019-01-31 2022-11-01 理想科学工業株式会社 容器
EP4183395A4 (en) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
MX2023000693A (es) 2020-07-15 2023-02-13 Taiho Pharmaceutical Co Ltd Inhibidor de egfr.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065898A2 (en) * 2008-12-05 2010-06-10 Principia Biopharma Inc. Egfr kinase knockdown via electrophilically enhanced inhibitors
WO2013118817A1 (ja) * 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) * 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩

Also Published As

Publication number Publication date
TWI905228B (zh) 2025-11-21
JP7391226B2 (ja) 2023-12-04
JPWO2022014638A1 (https=) 2022-01-20
US20230331730A1 (en) 2023-10-19
KR20230034341A (ko) 2023-03-09
MX2023000692A (es) 2023-02-13
CA3189457A1 (en) 2022-01-20
US12492208B2 (en) 2025-12-09
PH12023550116A1 (en) 2024-06-24
WO2022014638A1 (ja) 2022-01-20
BR112023000765A2 (pt) 2023-02-07
CN116249534A (zh) 2023-06-09
EP4183788A1 (en) 2023-05-24
MY207540A (en) 2025-03-04
TW202216717A (zh) 2022-05-01
CN116249534B (zh) 2025-03-25
EP4183788A4 (en) 2024-07-17
KR102914926B1 (ko) 2026-01-19
AU2021307245A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
KR102873219B1 (ko) Egfr 저해제
CN104854101B (zh) Alk激酶抑制剂
KR102640463B1 (ko) 피리미딘 화합물 또는 그 염
EP3395817B1 (en) Pyrido[1,2-a]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor
WO2022095910A1 (zh) 用作激酶抑制剂的化合物及其应用
WO2020224626A1 (zh) 用作激酶抑制剂的化合物及其应用
EP3878854A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
AU2021307245B2 (en) Crystal of pyrimidine compound
CN101454309B (zh) 焦谷氨酸衍生物的合成和用途
CA3189457C (en) Crystal of pyrimidine compound
RU2828232C1 (ru) Кристалл соединения пиримидина
HK40087564A (zh) 嘧啶化合物的结晶
HK40087564B (zh) 嘧啶化合物的结晶
RU2787992C1 (ru) Пиримидиновое соединение или его соль
HK40056369A (en) Pyrimidine compound or salt thereof
HK40056369B (zh) 嘧啶化合物或其盐

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)